A further analysis considering the possibly that, as previously reported, KRAS mutations, a decreased amount of the splicing variant KRAS4A relative to the splice variant KRAS4B, or an MSI-phenotype might influence the survival of colorectal cancer patients [26]–[28], failed to show any significant prognostic effect in our patients' cohort (Figure S2). The gene discussed is KRAS; the disease is colorectal cancer.